Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

INTRODUCTION: To examine the utility of sequential versus dual add-on approaches in patients who have type 2 diabetes and inadequate glycemic control with metformin therapy alone, we characterized the efficacy and safety of dual therapy with dapagliflozin or saxagliptin added to metformin in the ope...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Ther
Päätekijät: Mathieu, Chantal, Catrinoiu, Doina, Ranetti, Aurelian Emil, Johnsson, Eva, Hansen, Lars, Chen, Hungta, Garcia-Sanchez, Ricardo, Iqbal, Nayyar, Celiñski, Aleksander
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2018
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://ncbi.nlm.nih.gov/pubmed/29802530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0445-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia